News

Categories
  1. FDA gives go-ahead for MN166 (ibudilast) to begin phase 2b/3 clinical trials

    Approval for next phase of clinical trials puts ALS patients one step closer to accessing new treatment shown to slow disease progression.

    FDA Ibudilast molecule and pills

    Read more »
  2. Kalydeco (ivacaftor) now approved in Canada for children aged 1-2

    Based on promising results from phase III clinical trials, Health Canada has decided to extend the use of Kalydeco (ivacaftor) to include children aged 1 to 2 years. 

    toddler in park with bubles

    Read more »
  3. Children with cystic fibrosis have a chance to breathe easier

    A recent clinical trial indicates that Symkevi/Symdeko (tezacaftor/ivacaftor) can safely and effectively loosen thick, sticky mucus for children 6-11 years old.

    girl running through field

    Read more »
  4. New cancer medicine targets tumour biomarkers anywhere in the body

    The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).

    US flag thumbs up gesture

    Read more »
  5. Lung cancer medicine receives positive opinion in the EU

    CHMP's assessment supports EMA's approval of non-small cell lung cancer (NSCLC) medicine, Vizimpro (dacomitinib).

    EU approval OK hand gesture

    Read more »
  6. New study supports FDA's decision to approve Copiktra (duvelisib)

    Phase III trial shows that Copiktra (duvelisib) may be an option for patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.

    woman smiling sunny

    Read more »
  7. Onpattro (patisiran): the first RNAi therapeutic approved in the European Union

    Onpattro (patisiran) is a first-in-class treatment that slows down the progression of hereditary transthyretin amyloidosis (hATTR).

    EU approval OK hand gesture

    Read more »
  8. Cancer medicine, Lartruvo (olaratumab), does not prolong life

    After failing to show a clear benefit over chemotherapy on its own, both the FDA and EMA do not recommend Lartruvo (olaratumab) for use in combination with chemotherapy for new STS patients.

    old bench

    Read more »
  9. Reimbursement information on Spinraza (nusinersen)

    Over 50 countries have approved Spinraza (nusinersen), but not all have made it available to the patients who need it.

    stethoscope on money and med chart

    Read more »
  10. Erleada (apalutamide) gets positive opinion from the EMA

    New medicine shows statistically significant improvements for prostate cancer patients.

    backlit man on mountain arms out

    Read more »
  11. Truxima (rituximab) gains FDA approval as the first biosimilar for Non-Hodgkin's Lymphoma

    A new biosimilar, Truxima (rituximab), shows comparable results to the reference medicine, Rituxan (rituximab), and takes FDA one step further toward expanding patient access to medicines.

    approved stamp with stars

    Read more »
  12. Vyndaqel (tafamidis) prolongs life of FAP patients

    Positive news for patients with early-stage FAP; results from a Portuguese study show that a liver transplant or Vyndaqel may extend survivability.

    grandfather pointing into sea

    Read more »
  13. A new gene therapy on the horizon for SMA

    Zolgensma (onasemnogene abeparvovec-xxxx) to receive priority review by FDA as a one-time treatment of type 1 spinal muscular atrophy (SMA).

    baby outside reaching toward viewer

    Read more »
  14. Orkambi approved in Australia, will others follow?

    Australia provides reimbursement for cystic fibrosis medicine.

    family blowing bubbles

    Read more »
  15. Alunbrig (brigatinib) approved in Europe for another type of lung cancer

    The European Commission has approved Alunbrig (brigatinib) for the treatment of a specific type of lung cancer.

    eu stars

    Read more »
  16. Bavencio (avelumab) misses ovarian cancer trial endpoints

    A late-stage study testing Bavencio (avelumab) has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.

    woman backlit sun field

    Read more »
  17. Ocrevus (ocrelizumab) helps preserve hand and arm function in PPMS

    In an exploratory study Ocrevus (ocrelizumab) slowed down loss of function in the upper extremities for patients with primary progressive multiple sclerosis (PPMS).

    woman raised hands near water

    Read more »
  18. Newly approved in the EU: Durvalumab (Imfinzi) an immunotherapy for Stage III Lung Cancer

    Read more »
  19. Where data and humanity meet: an algorithm to improve medicine pricing models

    Industry NewsHow two professors imagine a better world for stakeholders in the medical industry. 

    Read more »
  20. Mystery around a high-risk leukaemia solved

    "These results offer a leap in understanding about this disease that provides a genetically based framework for designing clinical trials to develop more effective treatments of MPAL," 

    High-Risk Leukaemia

    Read more »
  21. New method promises fewer side effects from cancer drugs

    "In short, it will help produce drugs where we can be far more confident about where modifications are being made, so that side effects can be minimized in the future"

    Fewer Side Effects

    Read more »
  22. Breast Cancer: New indicators found to help in prognosis for the most aggressive form

    Researchers report a successful classification of triple breast cancer patients, which for the first time, would allow doctors to discern between those who can be cured and those who might suffer a relapse. 

    Triple Negative Breast Cancer

    Read more »
  23. CAR T cell approval may offer patients a new form of therapy

    Industry NewsAccording to study investigators, about a third of patients could benefit from this therapy that may offer remissions, relieve symptoms and save lives.

    Read more »
  24. Stem cells as a new drug delivery tool for childhood brain cancer?

    "This is a great avenue of exploration, particularly for the 30 percent of children who struggle or don't make it with standard therapy."

    Stem Cell drug delivery in Brain Cancer

    Read more »
  25. Deep brain stimulation leads to increased understanding of Parkinson's disease

    These findings increase our understanding of how the brain is affected by Parkinson's disease...

    Parkinsons' Deep Brain Stimulation

    Read more »
  26. Study finds that new Multiple Sclerosis drug slows down brain shrinkage

    "These findings provide a glimmer of hope for people with a form of multiple sclerosis that causes long-term disability but does not have many treatment options,"

    MS Progressive study

    Read more »
  27. New study uses focussed ultrasound to deliver anti-cancer drugs across the blood brain barrier

    "By laying the groundwork for more rational design and deeper understanding of focused-ultrasound-based treatment, our work could help improve treatment of any brain tumor -- primary or metastatic -- and could also revolutionize approaches to immunotherapy of tumors by improving localized delivery of tumor-killing immune cells."

    Blood Brain research

    Read more »
  28. Majority of former and current cancer patients are happy with their life

    "These findings of incredible mental flourishing even in the context of cancer is a wonderful testament to the resiliency of patients and an encouraging message for patients, their families and their health care providers" stated Fuller-Thomson.

    Cancer patients happy

    Read more »
  29. Keeping cancer out of breath blocks drug resistance

    "The best part is that our combined drug candidate was so much more effective than one of the most powerful cancer drugs on the market," said Jonathan Sessler

    cancer out of breath

    Read more »
  30. Acute leukemia: Drug trials show 50% cure rate

    "We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice's leukemia signs disappeared overnight," said Professor Ben-Neriah.

    Drug Trials 50% Cure rate

    Read more »
US 0